retatrutide type 2 diabetes trial results 2024 This data from Phase 3 clinical trials for was announced yesterday at @amdiabetesassn #ADA2026 ✓ We are fortunate to be living in a time where there multiple medications which safely reduce Retatrutide: A Triple Agonist Shaping

Its not yet approved for regular clinical use and is still being investigated, with Phase 3 trials currently underway

According to researchers from Johns Hopkins, women who take GLP-1 RAs lose an average of 11% of their starting weight after 43 weeks of treatment

I exercised more over the course of this experiment than in the past, partially because I didn't want to lose muscle and partially because I got a smartwatch that would tell me nudge me to exercise (it's fun to see number go up in training load, for example)

This finding is mirrored in human studies, where exogenous GLP-1 fails to enhance insulin secretion or reduce postprandial glucose levels in individuals who have undergone vagotomy (Plamboeck et al., 2013)

Early weight loss includes water as the body adjusts to reduced food intake and carbohydrate storage